-Reuters
HC Wainwright & Co. Maintains Buy on GT Biopharma, Lowers Price Target to $5
HC Wainwright & Co. analyst Robert Burns maintains GT Biopharma (NASDAQ:GTBP) with a Buy and lowers the price target from $25 to $5.
Related Posts
Reported Late Monday March 27, Edgio, Inc. Receives Notice From Nasdaq Stating That The Co Is Not In Compliance With The Requirements For Continued Listing Under Nasdaq Listing Rule 5250(c)(1), Has Until May 22,2023 To Submit Plan To Regain Compliance
Edgio, Inc. (NASDAQ:EGIO) (the "Company" ), today announced that it received an expected notice (the "Notice") on March 23, 2023 from The Nasdaq Stock Market LLC ("Nasdaq") stating that the
Piper Sandler Maintains Neutral on Riskified, Raises Price Target to $6
Piper Sandler analyst Brent Bracelin maintains Riskified (NYSE:RSKD) with a Neutral and raises the price target from $5 to $6.
Golden Minerals Announces $4.2M Public Offering
Golden Minerals Company ("Golden Minerals", "Golden" or the "Company") (NYSE:AUMN, TSX:AUMN) is pleased to announce the pricing of its public offering of an aggregate of 6,000,000 shares of its common stock (or common